Edward Rosfjord, PhD
Affiliations: | 2000- | Oncology | Pfizer Research Pearl River |
Google:
"Edward Rosfjord"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Angie Rizzino | grad student | 1990-1995 | University of Nebraska Medical Center |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Graziani EI, Sung M, Ma D, et al. (2020) . Molecular Cancer Therapeutics |
| Betts A, Clark T, Jasper P, et al. (2020) Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1. Journal of Pharmacokinetics and Pharmacodynamics |
| Mathur D, Root AR, Bugaj-Gaweda B, et al. (2020) A Novel GUCY2C-CD3 T cell Engaging Bispecific construct (PF-07062119) for the Treatment of Gastrointestinal Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Zhong W, Myers JS, Wang F, et al. (2020) Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors. Bmc Genomics. 21: 2 |
| Mathur D, Root A, Bugaj-Gaweda B, et al. (2020) Abstract 2283: A novel GUCY2C - CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors Immunology |
| Yao J, Mathur D, Yang S, et al. (2020) Abstract 4549: Evaluation of GUCY2c-CD3 bispecific targeting GI cancers in an orthotopic colorectal tumor model Immunology. 80: 4549-4549 |
| Arensman MD, Yang XS, Leahy DM, et al. (2019) Cystine-glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America |
| Sung MS, Hopf C, Upeslacis E, et al. (2018) Abstract 818: NG-HER2 ADC (PF-06804103) is superior to trastuzumab emtansine in a mouse 'avatar' head-to-head clinical trial Cancer Research. 78: 818-818 |
| Sung M, Tan X, Lu B, et al. (2017) Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1). Molecular Cancer Therapeutics |
| Damelin M, Bankovich A, Bernstein J, et al. (2017) A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Science Translational Medicine. 9 |